FDA green lights Priovant drug for rare skin disease

The FDA has approved Lisraya, a drug developed by Priovant, a Roivant subsidiary, for treating a rare skin disease. This marks the first approval of a drug licensed from Pfizer by Priovant, targeting multiple rare inflammatory conditions.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 28 Aug 2026 and 7 Sep 2026.